Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 3/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577890 | 0.83 | MAP4K1 (0.38) | TSHRTDO2MAP2K4ALDH1A1CYP1A2 | |
| SCHEMBL19568133 | 0.81 | JAK2 (0.38) | TSHRTDO2NR4A2MAP2K4ALDH1A1 | |
| SCHEMBL31381583 | 0.78 | PTPN6 (0.39) | TSHRTDO2MAP2K4ALDH1A1NPC1 | |
| SCHEMBL543204 | 0.75 | NOS1 (0.44) | TSHRTDO2NR4A2ALDH1A1IDO1 | |
| SCHEMBL13132270 | 0.75 | TDO2 (0.50) | TSHRTDO2MAP2K4ALDH1A1MEN1 | |
| SCHEMBL27789490 | 0.75 | TDO2 (0.36) | TDO2MAPTCYP1A2GSK3BIDO1 | |
| SCHEMBL15910597 | 0.72 | TDO2 (0.50) | TSHRTDO2MAP2K4ALDH1A1LMNA | |
| SCHEMBL459193 | 0.72 | TDO2 (0.53) | TSHRTDO2NR4A2MAPTIDO1 | |
| SCHEMBL2592578 | 0.72 | NR4A2 (0.48) | TSHRNR4A2MAP2K4ALDH1A1MEN1 | |
| SCHEMBL31158048 | 0.72 | TDO2 (0.53) | TSHRTDO2NR4A2MAPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2991654-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-08 | — | — | US | disclosed |
| US-10065967-B2 | Compounds that are ERK inhibitors | Merck, Sharp & Dohme Corp. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9745307-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745307-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | TSHR 3267/4885TDO2 4707/4885NR4A2 2880/4885 |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | TSHR 328/4885TDO2 153/4885NR4A2 1321/4885 |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | TSHR 3128/4885TDO2 4620/4885NR4A2 3122/4885 |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | TSHR 3128/4885TDO2 4620/4885NR4A2 3122/4885 |
| US-10065967-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | TSHR 3267/4885TDO2 4707/4885NR4A2 2880/4885 |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAP3K20, MAPK6 | TSHR 3840/4885TDO2 4437/4885NR4A2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.